Halozyme Therapeutics, Inc. (HALO) reported third-quarter 2024 adjusted earnings of $1.27 per share, which comprehensively beat the Zacks Consensus Estimate of 99 cents. The company had recorded adjusted earnings of 75 cents per share in the year-ago period.Total revenues in the third quarter increased 34% year over year to $290 million. Revenues surpassed the Zacks Consensus Estimate of $248 million.The top line was primarily driven by higher royalty payments from Roche (RHHBY) for Phesgo and J&J (JNJ) for ...

Financial Data and Key Metrics Changes - Total revenues increased by 34% to reach an all-time high of $290 million in Q3 2024, driven largely by a 36% increase in royalty revenue to $155 million [7][63] - Adjusted EBITDA grew by 60% to $183.6 million, while non-GAAP earnings per share increased by 69% to $1.27 [62][66] - The company raised its full-year revenue guidance to $970 million to $1.20 billion, representing a year-over-year increase of 17% to 23% [68][70] Business Line Data and Key Metrics Changes - Royalty revenues from subcutaneous DARZALEX, Phesgo, and VYVGART Hytrulo were the main drivers of growth, with DARZALEX sales increasing almost 23% and Phesgo sales up 58% [22][26][64] - Collaboration revenues rose significantly to $48.4 million, compared to $15 million in the prior year, due to the expansion of the Argenx collaboration [64] Market Data and Key Metrics Changes - The U.S. approval of Roche's TECENTRIQ and OCREVUS subcutaneous formulations is expected to expand market opportunities significantly, with Roche projecting a $2 billion market expansion for OCREVUS [10][31][76] - Analysts predict TECENTRIQ will achieve $5 billion in sales by 2028, with a significant portion coming from the conversion of intravenous to subcutaneous administration [30] Company Strategy and Development Direction - The company is focused on expanding its ENHANZE drug delivery technology through new partnerships and licensing agreements, with recent expansions including argenx's nomination of four additional targets [9][17] - The strategy emphasizes market growth rather than immediate conversion from IV to subcutaneous, particularly for OCREVUS, which aims to attract new prescribers [75][81] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continued double-digit growth driven by multiple product launches and regulatory approvals, setting the stage for a strong start to 2025 [72][54] - The company highlighted the importance of its intellectual property portfolio in supporting revenue streams and enabling new partnerships [55][60] Other Important Information - The company maintains a strong balance sheet with cash and marketable securities totaling $666.3 million as of September 30, 2024 [67] - The MDASE patent portfolio has been expanded, with nearly 100 patents granted or pending, providing additional opportunities for licensing [59][116] Q&A Session Summary Question: Current view on sub-Q conversion for OCREVUS and TECENTRIQ - Management clarified that OCREVUS aims for market growth rather than immediate conversion, projecting a $2 billion market expansion, while TECENTRIQ will focus on converting existing patients to subcutaneous [75][76][81] Question: Contextualizing the $2 billion market expansion for OCREVUS - Management indicated that the $2 billion is additional to the existing IV sales, suggesting a total market growth to approximately $11 billion [81] Question: Status of new collaboration deals before year-end - Management confirmed ongoing efforts to secure new deals, with guidance for collaboration revenue set at $130 million to $150 million [87][88] Question: Differentiation of MDASE from ENHANZE - Management explained that MDASE involves different structures and is not expected to infringe on existing ENHANZE partnerships, as they cater to different needs [111][114] Question: Examples of partners unable to work with ENHANZE - Management noted that partners might choose modified hyaluronidase if they cannot work with ENHANZE due to exclusive licensing agreements [120] Question: Drivers behind the collaboration revenue guidance - Management acknowledged a slight reduction in the top range of collaboration revenue guidance, attributing it to current visibility on potential deals [119]

Halozyme Therapeutics, Inc. Third Quarter 2024 Financial & Operating Results 1 NASDAQ: HALO October 31, 2024 Forward Looking Statements In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future growth, financial performance (including the Company's 2024 guidance and longer term financial outlook through 2028) and expectations for profitability, revenue (including e ...

Halozyme Therapeutics (HALO) reported $290.08 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 34.3%. EPS of $1.27 for the same period compares to $0.75 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $248.01 million, representing a surprise of +16.97%. The company delivered an EPS surprise of +28.28%, with the consensus EPS estimate being $0.99.While investors closely watch year-over-year changes in headline numbers -- revenue an ...

Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $0.99 per share. This compares to earnings of $0.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.28%. A quarter ago, it was expected that this biopharmaceutical company would post earnings of $0.78 per share when it actually produced earnings of $0.91, delivering a surprise of 16.67%.Over the last fou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its char ...

Exhibit 99.1 HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 million Net Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 million GAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.27 Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of ...

Total Revenue Increased 34% YOY to $290 million and Royalty Revenue Increased 36% YOY to $155 millionNet Income Increased 67% YOY to $137 million and Adjusted EBITDA Increased 60% YOY to $184 millionGAAP Diluted EPS Increased 72% YOY to $1.05 and Non-GAAP Diluted EPS Increased 69% YOY to $1.271Raised 2024 Financial Guidance Ranges for Total Revenue of $970-$1,020 million, Representing YOY Growth of 17%-23%, Adjusted EBITDA of $595-$625 million, Representing YOY Growth of 40%-47%, and Non-GAAP Diluted EPS of ...

Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX FASPRO® and SC through 2032Reiterates 2024 Royalty Revenue Guidance of $520-555 million and Expectations to Generate >$1 billion in 2027Conference Call Scheduled Today, Thursday, October 24 at 5:30am PT/8:30am ETSAN DIEGO, Oct. 24, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today provided an update following a decision by the Opposition Division of the European Patent Office ("EPO") to revoke one of the Jansse ...

SAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its third quarter 2024 financial and operating results on Thursday, October 31, 2024, following the close of trading.Halozyme will host a conference call on Thursday, October 31, 2024 at 1:30 p.m. PT/4:30 p.m. ET to discuss the results. The conference call may be accessed live with pre-registration via this link: https://registrations.events/direct/Q4I7813747.A live webcast and re ...